US Stock Market Movement: Jielong plunges on October 28th as Phase III trial terminates and overall survival endpoint unlikely to be reached

Jielong October 28 Major Drop Interpretation

Keywords: Phase III trial termination, overall survival endpoint unattainable

On October 28, 2026, Jielong, following the recommendation of the independent data monitoring committee, decided to terminate the IMpactMF Phase III trial due to the expected failure to reach the primary endpoint of overall survival; this decision impacts the clinical development prospects of Imatasertib for relapsed/refractory myelofibrosis after JAK inhibitor treatment. After the announcement, the stock price dropped.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)